Acute promyelocytic leukemia (APL) has historically been one of the most aggressive forms of leukemia and an oncological emergency, characterized by rapid progression and high early mortality rates.¹ Traditional chemotherapy treatments oft

Acute promyelocytic leukemia (APL) is a rapidly fatal disease without timely treatment.¹ A recent breakthrough from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) is changing the global treatment landscape of APL with the